Skip to main content


Actemra FDA Approved for Systemic Sclerosis Interstitial Lung Disease

Genentech announced yesterday that the US Food and Drug Administration approved tocilizumab (Actemra) for the treatment of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), specifically indicated for the slowing the rate of decline in pulmonary function in adults SSc-ILD.

RheumNow Podcast – Pounds of Prevention (3.5.2021)

Dr. Jack Cush reviews and discusses nearly a dozen news reports and journal articles from the past week on

Baricitinib Therapy in Covid-19 Pneumonia

The NEJM has published the results of the ACCT-2 Study,  a double-blind, randomized, placebo-controlled trial evaluating baricitinib, an inhibitor of Janus kinase 1 (JAK1) and JAK2, plus remdesivir in hospitalized adults with Covid-19. The primary outcome was the time to recovery.

Weight Loss to Avert Risk of Gout

Analysis of the NHANES population survey data shows weight gain during adulthood increases the risk of gout and that maintaining normal weight could reduce the overall gout risk by nearly 33%.

Paucity of Effectiveness Research on Telemedicine in RA

A systematic review of telehealth in delivering equivalent care in RA patients demonstrates there is limited evidence that virtual RA care is equivalent to conventional face-to-face care. Despite current widespread use, there is a great need for credible well-designed research that will address comparable patient outcomes, implementation strategies and long‐term health system consequences. 

Combo Therapy Boosts Response in Uncontrolled Gout

MedPage Today

The addition of an immunomodulating agent to pegloticase (Krystexxa) among patients with uncontrolled gout significantly improved response rates, a systematic literature review found.

NEJM: Interleukin-6 Inhibition in Critically-Ill COVID-19

The pendulum and jury are wavering with regard to the benefits of interleukin-6 receptor antagonists in COVID-19; the current NEJM reports the results of a study favoring such biologic therapy in in critically ill COVID-19 patients.

MAXIMISE Trial - Secukinumab Efficacy in Psoriatic Spondylitis Patients

The results of the novel MAXIMISE trial have been published, demonstrating that secukinumab significantly improved axial signs and symptoms in psoriatic arthritis patients with axial manifestations with inadequate NSAID response.

RheumNow Podcast – Sweet Lies or Hard Truths? (2.26.2021)

Dr. Jack Cush reviews and discusses the news and Journal reports from the past week on

Measureable Benefits to Treat-to-Target Management in RA

Desai and colleagues have published that when a learning collaborative group focused on a treat‐to‐target approach was compared to usual care, a modest but significant impact on implementation, treatment changes and patient outcomes in RA patients managed with a treat‐to‐target approach was seen.

Higher Lupus Mortality Among Minority Populations

The February 19th MMWR reports that higher mortality rates in certain patients with systemic lupus erythematosus (SLE); data based on recent San Francisco County statistics showing a four fold higher mortality among Asian and Hispanic/Latina females with SLE.

ANAGO Study - Anakinra for Gout Flare

MedPage Today
The interleukin (IL)-1 receptor antagonist anakinra (Kineret) was not superior to triamcinolone for relieving gout flares, but had similar effects for pain reduction as the glucocorticoid, a randomized phase II study found.